NO3102476T3 - - Google Patents

Info

Publication number
NO3102476T3
NO3102476T3 NO15710770A NO15710770A NO3102476T3 NO 3102476 T3 NO3102476 T3 NO 3102476T3 NO 15710770 A NO15710770 A NO 15710770A NO 15710770 A NO15710770 A NO 15710770A NO 3102476 T3 NO3102476 T3 NO 3102476T3
Authority
NO
Norway
Application number
NO15710770A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO3102476T3 publication Critical patent/NO3102476T3/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/14—Eye parts, e.g. lenses or corneal implants; Artificial eyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Prostheses (AREA)
  • Polyesters Or Polycarbonates (AREA)
NO15710770A 2013-10-31 2015-03-18 NO3102476T3 (cg-RX-API-DMAC10.html)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361898241P 2013-10-31 2013-10-31

Publications (1)

Publication Number Publication Date
NO3102476T3 true NO3102476T3 (cg-RX-API-DMAC10.html) 2018-05-26

Family

ID=51982758

Family Applications (1)

Application Number Title Priority Date Filing Date
NO15710770A NO3102476T3 (cg-RX-API-DMAC10.html) 2013-10-31 2015-03-18

Country Status (28)

Country Link
US (7) US9492316B2 (cg-RX-API-DMAC10.html)
EP (5) EP4046628A1 (cg-RX-API-DMAC10.html)
JP (2) JP6482547B2 (cg-RX-API-DMAC10.html)
KR (1) KR102307281B1 (cg-RX-API-DMAC10.html)
CN (2) CN105682645B (cg-RX-API-DMAC10.html)
AU (3) AU2014342017B2 (cg-RX-API-DMAC10.html)
BR (1) BR112016009575B1 (cg-RX-API-DMAC10.html)
CA (1) CA2926515C (cg-RX-API-DMAC10.html)
CL (1) CL2016001041A1 (cg-RX-API-DMAC10.html)
CY (2) CY1119961T1 (cg-RX-API-DMAC10.html)
DK (2) DK3351239T3 (cg-RX-API-DMAC10.html)
ES (2) ES2661666T3 (cg-RX-API-DMAC10.html)
HU (2) HUE050902T2 (cg-RX-API-DMAC10.html)
IL (2) IL244859B (cg-RX-API-DMAC10.html)
MX (2) MX2016005508A (cg-RX-API-DMAC10.html)
MY (1) MY177958A (cg-RX-API-DMAC10.html)
NO (1) NO3102476T3 (cg-RX-API-DMAC10.html)
PH (1) PH12016500767A1 (cg-RX-API-DMAC10.html)
PL (2) PL3062775T3 (cg-RX-API-DMAC10.html)
PT (2) PT3351239T (cg-RX-API-DMAC10.html)
RU (1) RU2650614C2 (cg-RX-API-DMAC10.html)
SA (1) SA516371022B1 (cg-RX-API-DMAC10.html)
SG (2) SG11201603383VA (cg-RX-API-DMAC10.html)
SI (2) SI3062775T1 (cg-RX-API-DMAC10.html)
TR (1) TR201802759T4 (cg-RX-API-DMAC10.html)
UA (1) UA119853C2 (cg-RX-API-DMAC10.html)
WO (1) WO2015066548A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201602556B (cg-RX-API-DMAC10.html)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7431710B2 (en) 2002-04-08 2008-10-07 Glaukos Corporation Ocular implants with anchors and methods thereof
US8846073B2 (en) * 2006-12-19 2014-09-30 Allergan, Inc. Low temperature processes for making cyclic lipid implants for intraocular use
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
JP5937004B2 (ja) 2009-05-18 2016-06-22 ドーズ メディカル コーポレーションDose Medical Corporation 薬剤溶出眼内インプラント
US12478503B2 (en) 2009-05-18 2025-11-25 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
US9668915B2 (en) 2010-11-24 2017-06-06 Dose Medical Corporation Drug eluting ocular implant
US10245178B1 (en) 2011-06-07 2019-04-02 Glaukos Corporation Anterior chamber drug-eluting ocular implant
EP4046628A1 (en) * 2013-10-31 2022-08-24 Allergan, Inc. Prostamide-containing intraocular implants and methods of use thereof
US20160296627A1 (en) * 2013-12-06 2016-10-13 Envisia Therapeutics Inc. Intracameral implant for treatment of an ocular condition
AU2015266850B2 (en) 2014-05-29 2019-12-05 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
HK1249460A1 (zh) 2015-03-06 2018-11-02 Aerie Pharmaceuticals, Inc. 植入物施用器和植入物的施用方法
US20210228408A1 (en) * 2015-07-23 2021-07-29 Allergan, Inc. Glaucoma Treatment Via Intracameral Ocular Implants
CN115337254A (zh) 2015-07-23 2022-11-15 爱瑞制药公司 用于治疗眼病的玻璃体内药物递送系统
WO2017040853A1 (en) 2015-09-02 2017-03-09 Glaukos Corporation Drug delivery implants with bi-directional delivery capacity
KR20180058758A (ko) 2015-09-22 2018-06-01 그레이버그 비젼, 인크. 안구 장애의 치료를 위한 화합물 및 조성물
US11564833B2 (en) 2015-09-25 2023-01-31 Glaukos Corporation Punctal implants with controlled drug delivery features and methods of using same
CA3022830A1 (en) 2016-04-20 2017-10-26 Harold Alexander Heitzmann Bioresorbable ocular drug delivery device
CN114532976A (zh) 2016-05-31 2022-05-27 酷拉公司 可植入眼压传感器和使用方法
AU2017321980B2 (en) * 2016-09-02 2020-04-30 Alcon Inc. Implant applicators
US20190192341A1 (en) * 2017-11-09 2019-06-27 Allergan, Inc. Sustained-Release Implants for Lowering Intraocular Pressure with Extended Duration of Effect
US20210121534A1 (en) * 2018-06-19 2021-04-29 Cella Therapeutics, Llc Sustained-release drug delivery systems comprising an intraocular pressure lowering agent, a cnp compound, an npr-b compound, a tie-2 agonist, or neurotrophic agent for use for treating glaucoma or ocular hypertension
WO2020047144A2 (en) * 2018-08-30 2020-03-05 Liu Yunxiang Ophthalmic formulations, process for preparing the same and method for administering the same
CN113301886A (zh) * 2018-12-21 2021-08-24 瑞瓦纳治疗有限公司 包被的眼部植入物
US12491263B2 (en) * 2019-05-13 2025-12-09 University of Pittsburgh—of the Commonwealth System of Higher Education Polymer-based implant for retinal therapy and methods of making and using the same
CA3144406A1 (en) 2019-06-27 2020-12-30 Layerbio, Inc. Ocular device delivery methods and systems
CN115066232B (zh) 2020-02-06 2024-12-10 视尔普斯眼科公司 用于治疗眼病的组合物和方法
EP3936113A1 (en) * 2020-07-07 2022-01-12 Occlugel Hydrophilic degradable microsphere for delivering travoprost
EP4178506A1 (en) 2020-07-10 2023-05-17 Allergan, Inc. Posterior chamber delivery device for sustained release implant
JP7879845B2 (ja) * 2020-07-21 2026-06-24 アラーガン、インコーポレイテッド プロスタミドが高充填された眼内インプラント
BR112023022705A2 (pt) 2021-04-30 2024-01-16 Perfuse Therapeutics Inc Composições farmacêuticas e sistemas de entrega intravítrea de fármacos para o tratamento de doenças oculares
WO2022251710A2 (en) 2021-05-28 2022-12-01 Sight Sciences, Inc. Intraocular devices, systems, and methods
USD1137672S1 (en) 2024-08-27 2026-07-28 Glaukos Corporation Drug eluting ocular implant
US12458535B1 (en) 2025-04-25 2025-11-04 Michael Reynard Endothelial-integrated stent for Schlemm's canal and controlled aqueous humor outflow

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3749776A (en) 1970-08-28 1973-07-31 Allergan Pharma Method for blocking prostaglandin activity
US6309669B1 (en) 1984-03-16 2001-10-30 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix
CA1311686C (en) 1986-06-25 1992-12-22 John Weldon Shell Controlled release bioerodible drug delivery system
US4853224A (en) 1987-12-22 1989-08-01 Visionex Biodegradable ocular implants
US4997652A (en) 1987-12-22 1991-03-05 Visionex Biodegradable ocular implants
US5028624A (en) 1989-07-27 1991-07-02 Allergan, Inc. Intraocular pressure reducing 9,15-diacyl prostaglandins
US5034413A (en) 1989-07-27 1991-07-23 Allergan, Inc. Intraocular pressure reducing 9,11-diacyl prostaglandins
CA2021316C (en) 1989-07-27 2000-10-24 Ming Fai Chan Intraocular pressure reducing 11-acyl prostaglandins
US4994274A (en) 1989-07-27 1991-02-19 Allergan, Inc. Intraocular pressure reducing 11,15-diacyl prostaglandins and method of using
US5164188A (en) 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
US6602900B2 (en) 1992-09-21 2003-08-05 Allergan, Inc. Cyclopentane heptan(ENE)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US5834498A (en) 1992-09-21 1998-11-10 Allergan Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US5972991A (en) 1992-09-21 1999-10-26 Allergan Cyclopentane heptan(ene) oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US5688819A (en) 1992-09-21 1997-11-18 Allergan Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
MY113268A (en) 1992-12-29 2002-01-31 Insite Vision Incorporated Plasticized bioerodible controlled delivery system
US5994341A (en) 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
US5443505A (en) 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US6124344A (en) 1993-12-28 2000-09-26 Allergan Sales, Inc. Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US5545665A (en) 1993-12-28 1996-08-13 Allergan Cyclopentane(ene) heptenoic or heptanoic acids and derivatives thereof useful as therapeutic agents
US5516522A (en) 1994-03-14 1996-05-14 Board Of Supervisors Of Louisiana State University Biodegradable porous device for long-term drug delivery with constant rate release and method of making the same
US6294563B1 (en) 1994-10-27 2001-09-25 Allergan Sales, Inc. Combinations of prostaglandins and brimonidine or derivatives thereof
US5585401A (en) 1994-12-09 1996-12-17 The Reents Of The University Of California Method for enhancing outflow of aqueous humor in treatment of glaucoma
US6369116B1 (en) 1995-06-02 2002-04-09 Oculex Pharmaceuticals, Inc. Composition and method for treating glaucoma
US5741810A (en) 1996-02-29 1998-04-21 Allergan Cyclopentane heptan(ene)oic acid, 2- heteroarylalkenyl derivatives as therapeutic agents
US6395787B1 (en) 2000-02-08 2002-05-28 Allergan Sales, Inc. Ocular hypotensive lipids
US7708711B2 (en) 2000-04-14 2010-05-04 Glaukos Corporation Ocular implant with therapeutic agents and methods thereof
US20040175410A1 (en) 2000-04-26 2004-09-09 Control Delivery Systems, Inc. Sustained release device and method for ocular delivery of carbonic anhydrase inhibitors
US6726918B1 (en) 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
PE20020146A1 (es) 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
EP1365811A2 (en) 2000-07-14 2003-12-03 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
US6699493B2 (en) 2000-11-29 2004-03-02 Oculex Pharmaceuticals, Inc. Method for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
WO2002089767A1 (en) 2001-05-03 2002-11-14 Massachusetts Eye And Ear Infirmary Implantable drug delivery device and use thereof
US20030220376A1 (en) 2001-08-10 2003-11-27 Pharmacia Corporation Methods for treating carbonic anhydrase mediated disorders
GB0122318D0 (en) 2001-09-14 2001-11-07 Novartis Ag Organic compounds
KR101160780B1 (ko) 2002-08-29 2012-06-27 산텐 세이야꾸 가부시키가이샤 Rho 키나아제 억제제 및 프로스타글란딘류를 포함하는 녹내장 치료제
US6899717B2 (en) 2002-09-18 2005-05-31 Allergan, Inc. Methods and apparatus for delivery of ocular implants
US7368126B2 (en) 2002-11-06 2008-05-06 Guohua Chen Controlled release depot formulations
US20040137059A1 (en) * 2003-01-09 2004-07-15 Thierry Nivaggioli Biodegradable ocular implant
US20090148527A1 (en) 2007-12-07 2009-06-11 Robinson Michael R Intraocular formulation
US7169807B2 (en) 2004-04-09 2007-01-30 Allergan, Inc. 10-Hydroxy-11-dihydroprostaglandin analogs as selective EP4 agonists
US9498457B2 (en) * 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
US7993634B2 (en) 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US20230026451A1 (en) * 2004-04-30 2023-01-26 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
US20050244458A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular neuropathies
US8685435B2 (en) 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
US20050244463A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
US7589057B2 (en) 2004-04-30 2009-09-15 Allergan, Inc. Oil-in-water method for making alpha-2 agonist polymeric drug delivery systems
US20060182781A1 (en) 2004-04-30 2006-08-17 Allergan, Inc. Methods for treating ocular conditions with cyclic lipid contraining microparticles
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US20050244469A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
US8119154B2 (en) 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
US20070212395A1 (en) 2006-03-08 2007-09-13 Allergan, Inc. Ocular therapy using sirtuin-activating agents
US8147865B2 (en) 2004-04-30 2012-04-03 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US8673341B2 (en) 2004-04-30 2014-03-18 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
US20050282902A1 (en) 2004-06-22 2005-12-22 Allergan, Inc. Abnormal cannabidiols as agents for lowering intraocular pressure
US7101904B2 (en) 2004-08-10 2006-09-05 Allergan, Inc. Cyclopentane heptan(ENE)OIC acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US7473738B2 (en) * 2004-09-30 2009-01-06 Johnson & Johnson Vision Care, Inc. Lactam polymer derivatives
CN101437478A (zh) * 2004-10-04 2009-05-20 Qlt美国有限公司 聚合送递制剂的眼部送递
CA2582374A1 (en) 2004-10-04 2006-04-20 Qlt Usa, Inc. Ocular delivery of polymeric delivery formulations
US7101906B2 (en) 2004-11-16 2006-09-05 Allergan, Inc. 2,3,4-substituted cyclopentanones as therapeutic agents
US7183324B2 (en) 2004-11-23 2007-02-27 Allergan, Inc. 2,3,4-substituted cyclopentanones as therapeutic agents
NZ555945A (en) 2005-01-14 2011-01-28 Allergan Inc Substituted cyclopentanes or cyclopentanones for the treatment of ocular hypertensive conditions
EP1856042B1 (en) 2005-03-10 2012-06-27 Allergan, Inc. Substituted gamma lactams as therapeutic agents
CA2602535A1 (en) 2005-05-06 2006-11-16 Allergan, Inc. Substituted beta-lactams and their use in medicine
US8039507B2 (en) 2005-06-29 2011-10-18 Allergan, Inc. Therapeutic substituted gamma lactams
DE102005033101A1 (de) 2005-07-15 2007-01-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Resorbierbare Polyetherester und ihre Verwendung zur Herstellung von medizinischen Implantaten
JP5122460B2 (ja) 2005-09-16 2013-01-16 アラーガン、インコーポレイテッド 治療薬の眼内輸送のための組成物および方法
US20090082321A1 (en) 2007-09-21 2009-03-26 Allergan, Inc. Steroid containing drug delivery systems
AU2006311942B2 (en) 2005-11-03 2012-11-22 Allergan, Inc. Prostaglandins and analogues as agents for lowering intraocular pressure
PE20080142A1 (es) 2006-03-15 2008-04-14 Boehringer Ingelheim Int Beta-agonistas enantiomericamente puros y sus procedimientos de preparacion
AU2007226957B2 (en) 2006-03-20 2013-08-15 Allergan, Inc. Substituted gamma lactams as prostaglandin EP2 agonists
US7439372B2 (en) 2006-05-03 2008-10-21 Allergan, Inc. Therapeutic compounds
US7491844B2 (en) 2006-05-04 2009-02-17 Allergan, Inc. Therapeutic cyclopentane derivatives
US20070293873A1 (en) 2006-06-19 2007-12-20 Allergan, Inc. Apparatus and methods for implanting particulate ocular implants
US20070298073A1 (en) 2006-06-23 2007-12-27 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US8802128B2 (en) 2006-06-23 2014-08-12 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US9039761B2 (en) * 2006-08-04 2015-05-26 Allergan, Inc. Ocular implant delivery assemblies with distal caps
US8969415B2 (en) 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
US8846073B2 (en) 2006-12-19 2014-09-30 Allergan, Inc. Low temperature processes for making cyclic lipid implants for intraocular use
US8231892B2 (en) 2007-05-24 2012-07-31 Allergan, Inc. Biodegradable drug delivery system
US20090081277A1 (en) 2007-09-21 2009-03-26 Allergan, Inc. Pharmaceutical formulations and methods for treating ocular conditions
US7740604B2 (en) 2007-09-24 2010-06-22 Ivantis, Inc. Ocular implants for placement in schlemm's canal
WO2009143288A1 (en) 2008-05-20 2009-11-26 Yale University Biodegradable sustained-release polymeric microparticulates comprising a hydrophobic drug and determined for ophthalmic use
US20100098772A1 (en) 2008-10-21 2010-04-22 Allergan, Inc. Drug delivery systems and methods for treating neovascularization
US20100104654A1 (en) * 2008-10-27 2010-04-29 Allergan, Inc. Prostaglandin and prostamide drug delivery systems and intraocular therapeutic uses thereof
US9095506B2 (en) 2008-11-17 2015-08-04 Allergan, Inc. Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof
BRPI1007318A2 (pt) * 2009-01-23 2019-04-09 Qlt Inc. distribuição com liberação sustentada de um ou mais agentes.
US20100247606A1 (en) 2009-03-25 2010-09-30 Allergan, Inc. Intraocular sustained release drug delivery systems and methods for treating ocular conditions
US20120245505A1 (en) 2009-12-16 2012-09-27 Robinson Michael R Intracameral devices for sustained delivery
KR102337046B1 (ko) 2010-01-22 2021-12-08 알러간, 인코포레이티드 전방내 서방성 치료제 이식물
US20130071349A1 (en) * 2010-03-02 2013-03-21 Allergan, Inc. Biodegradable polymers for lowering intraocular pressure
JP2014512392A (ja) 2011-04-22 2014-05-22 アラーガン インコーポレイテッド 疼痛を治療するための脂肪酸アミド加水分解酵素阻害剤
EP3494959A3 (en) * 2011-04-29 2019-09-11 Allergan, Inc. Sustained release latanoprost implant
EP4046628A1 (en) * 2013-10-31 2022-08-24 Allergan, Inc. Prostamide-containing intraocular implants and methods of use thereof
US20190192341A1 (en) * 2017-11-09 2019-06-27 Allergan, Inc. Sustained-Release Implants for Lowering Intraocular Pressure with Extended Duration of Effect
JP7879845B2 (ja) * 2020-07-21 2026-06-24 アラーガン、インコーポレイテッド プロスタミドが高充填された眼内インプラント

Also Published As

Publication number Publication date
MX2016005508A (es) 2016-08-03
SA516371022B1 (ar) 2018-03-04
RU2650614C2 (ru) 2018-04-16
AU2020201778B2 (en) 2021-11-04
PL3351239T3 (pl) 2020-12-28
AU2022200742B2 (en) 2024-08-22
US20150118279A1 (en) 2015-04-30
AU2014342017A1 (en) 2016-06-02
HK1258014A1 (en) 2019-11-01
EP3062775A1 (en) 2016-09-07
ZA201602556B (en) 2017-06-28
EP3351239B1 (en) 2020-04-01
AU2020201778A1 (en) 2020-03-26
US20260183308A1 (en) 2026-07-02
EP3351239A1 (en) 2018-07-25
CY1123077T1 (el) 2021-10-29
HUE036554T2 (hu) 2018-07-30
EP3669865A1 (en) 2020-06-24
BR112016009575B1 (pt) 2022-12-13
JP2017500282A (ja) 2017-01-05
PH12016500767B1 (en) 2016-06-20
AU2022200742A1 (en) 2022-02-24
IL244859B (en) 2019-08-29
ES2661666T3 (es) 2018-04-03
EP4406535A2 (en) 2024-07-31
CY1119961T1 (el) 2018-12-12
IL244859A0 (en) 2016-05-31
EP3062775B1 (en) 2017-12-06
KR102307281B1 (ko) 2021-09-29
US9492316B2 (en) 2016-11-15
SI3351239T1 (sl) 2020-09-30
WO2015066548A1 (en) 2015-05-07
TR201802759T4 (tr) 2018-03-21
JP6482547B2 (ja) 2019-03-13
IL268976B (en) 2021-04-29
PH12016500767A1 (en) 2016-06-20
HUE050902T2 (hu) 2021-01-28
PL3062775T3 (pl) 2018-05-30
DK3351239T3 (da) 2020-06-29
US20220218721A1 (en) 2022-07-14
SG10201800978UA (en) 2018-03-28
US20180271878A1 (en) 2018-09-27
AU2014342017B2 (en) 2020-01-23
US9980974B2 (en) 2018-05-29
KR20160077121A (ko) 2016-07-01
JP6814829B2 (ja) 2021-01-20
IL268976A (en) 2019-10-31
JP2019088881A (ja) 2019-06-13
RU2016116378A (ru) 2017-12-01
PT3351239T (pt) 2020-07-03
CN105682645B (zh) 2019-09-06
US20170056412A1 (en) 2017-03-02
PT3062775T (pt) 2018-03-06
SI3062775T1 (en) 2018-05-31
EP4046628A1 (en) 2022-08-24
EP4406535A3 (en) 2024-11-06
CA2926515C (en) 2020-11-24
CN110302138B (zh) 2022-09-30
CN110302138A (zh) 2019-10-08
DK3062775T3 (en) 2018-03-12
NZ718992A (en) 2021-11-26
BR112016009575A2 (pt) 2017-08-01
MX2020002381A (es) 2020-07-22
US20210030766A1 (en) 2021-02-04
UA119853C2 (uk) 2019-08-27
CN105682645A (zh) 2016-06-15
SG11201603383VA (en) 2016-05-30
CA2926515A1 (en) 2015-05-07
ES2805880T3 (es) 2021-02-15
MY177958A (en) 2020-09-28
US20240108635A1 (en) 2024-04-04
CL2016001041A1 (es) 2016-10-28

Similar Documents

Publication Publication Date Title
AP2016009275A0 (cg-RX-API-DMAC10.html)
BR112016009990A2 (cg-RX-API-DMAC10.html)
BR112015007533A2 (cg-RX-API-DMAC10.html)
BR112014017739A2 (cg-RX-API-DMAC10.html)
BR112014018502A2 (cg-RX-API-DMAC10.html)
BR112014018516A2 (cg-RX-API-DMAC10.html)
BR112014017765A2 (cg-RX-API-DMAC10.html)
BR112014018480A2 (cg-RX-API-DMAC10.html)
BR112014020341A2 (cg-RX-API-DMAC10.html)
BR112014017669A2 (cg-RX-API-DMAC10.html)
BR112016001250A2 (cg-RX-API-DMAC10.html)
BR112014018468A2 (cg-RX-API-DMAC10.html)
BR112016011663A2 (cg-RX-API-DMAC10.html)
BR112014018207A2 (cg-RX-API-DMAC10.html)
BR112014019204A2 (cg-RX-API-DMAC10.html)
BR112014017901A2 (cg-RX-API-DMAC10.html)
BR112014017745A2 (cg-RX-API-DMAC10.html)
BR112014017653A2 (cg-RX-API-DMAC10.html)
BR112014018578A2 (cg-RX-API-DMAC10.html)
BR112014017601A2 (cg-RX-API-DMAC10.html)
BR112015015312A2 (cg-RX-API-DMAC10.html)
BR112014024039A2 (cg-RX-API-DMAC10.html)
BR112014018353A2 (cg-RX-API-DMAC10.html)
BR112014019048A2 (cg-RX-API-DMAC10.html)
BR112014018514A2 (cg-RX-API-DMAC10.html)